Evidence map›Paper›PMID 39554473›Full record

ArticleInfection and drug resistance2024

Clinical Features of Patients with COVID-19 Recurrence During Hospitalization in the Omicron Variant Surge.

Masafumi Seki, Chie Kubosawa, Makoto Ono, Fumitaka Kamoshita, Atsuko Shimizu, Kotaro Mitsutake

Abstract read
In one paragraph

Article in Infection and drug resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Masafumi SekiDivision of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, Japan.ORCID 0000-0001-5414-8148
Chie KubosawaDivision of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, Japan.
Makoto OnoDivision of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, Japan.
Fumitaka KamoshitaDivision of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, Japan.
Atsuko ShimizuDivision of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, Japan.
Kotaro MitsutakeDivision of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, Japan.ORCID 0000-0002-2429-511X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Repeat positive results for SARS-CoV-2 by antigen detection test/RT-PCR in recovered COVID-19 patients were not very rare even when omicron variants became dominant, but the clinical features of patients with recurrent COVID-19 during hospitalization are still unclear. Methods: The clinical characteristics of patients with recurrent COVID-19 during hospitalization were retrospectively investigated from January 2023 to December 2023. Results: Recurrence of COVID-19 was found in 7 of 275 (2.5%) patients during hospitalization. Their mean age was 80.3 (74-89) years, and 4 of 7 (57.1%) patients were hospitalized on the hematology ward with B cell/non-Hodgkin lymphoma. These 4 lymphoma patients had been vaccinated, but the other 3 patients hospitalized on the emergency ward and the neurology ward had not been vaccinated. Of the 7 patients, 6 (85.7%) were initially treated with remdesivir (RDV), but only 3 patients were re-treated with RDV, and the other 4 patients were successfully re-treated with oral 3C-like protease inhibitors, such as ensitrelvir (ESV) and nirmatrelvir/ritonavir (N/R). Conclusion: These data suggest that COVID-19 recurrence was found in patients with hematological disorders, such as lymphoma, and/or patients with no vaccination history. However, these patients were treated successfully by re-administration of anti-SARS-CoV-2 agents, including ESV and N/R.

Indexed as

Anti-CD20+ B cell depletionensitrelvirnirmatrelvir/ritonavirremdesivirrituximabSARS-CoV-2

Identifiers

PMID39554473
PMCPMC11568766

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.